Trials / Completed
CompletedNCT00110955
Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy
A Randomized, Double-Blind, Placebo-Controlled Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 391 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare the effect of darbepoetin alfa against placebo for the treatment of anemia in subjects with non-myeloid malignancies receiving multicycle chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Darbepoetin alfa | Q3W 300 mcg darbepoetin alfa |
| DRUG | Placebo | Q3W dosing of placebo |
Timeline
- Start date
- 2004-02-01
- Primary completion
- 2005-03-01
- Completion
- 2005-04-01
- First posted
- 2005-05-17
- Last updated
- 2010-01-15
Source: ClinicalTrials.gov record NCT00110955. Inclusion in this directory is not an endorsement.